POLA1: A Potential Drug Target and Biomarker (G5422)

Target Name: POLA1

NCBI ID: G5422

POLA1

POLA1: A Potential Drug Target and Biomarker

Pola1 is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug may have significant implications for the treatment of these diseases.

The Pola1 gene is located on chromosome 18 and encodes a protein known as poly(ADP-ribose) polymerase (PARP). PARP is a enzyme that plays a crucial role in the regulation of DNA replication and repair. It is highly conserved and has been found to be involved in various cellular processes, including cell growth, apoptosis, and DNA replication.

One of the unique features of Pola1 is its ability to form inclusion bodies, which are large aggregates of the protein that can be detected in the cells of individuals with certain genetic disorders. This feature has led to the conclusion that Pola1 may be involved in the development and progression of some diseases.

Pola1 has also been shown to be involved in the regulation of cell death, which is a crucial aspect of many diseases, including cancer. Studies have shown that when cells are exposed to certain stressors, such as chemotherapy drugs, they can trigger programmed cell death, also known as apoptosis. By participating in the regulation of cell death, Pola1 may be a potential drug target for cancer.

Another potential drug target for Pola1 is its role in the regulation of neurodegenerative disorders. Many of these disorders, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. It is thought that the underlying cause of these disorders may be the dysfunction of PARP, which has been shown to be involved in the regulation of neurogenesis and the maintenance of brain cells.

In addition to its potential drug target potential, Pola1 has also been identified as a potential biomarker for various diseases. Its inclusion in inclusion bodies has been observed in a variety of genetic disorders, including those that are characterized by the progressive loss of brain cells. This suggests that Pola1 may be a useful biomarker for the detection and diagnosis of these disorders.

The potential of Pola1 as a drug target and biomarker is significant, and further research is needed to fully understand its role in these diseases. Many researchers are currently working to identify small molecules that can inhibit the activity of Pola1 and use them as potential drugs for the treatment of various diseases. If successful, these drugs may have a significant impact on the treatment of these disorders and improve the quality of life for those affected.

In conclusion, Pola1 is a gene that has the potential to be a drug target and biomarker for a variety of diseases. Its unique structure and function make it an attractive target for researchers to study, and its potential as a drug or biomarker has significant implications for the treatment of these disorders. Further research is needed to fully understand its role in these diseases and to identify small molecules that can inhibit its activity. If successful, these drugs may have a significant impact on the treatment of these disorders and improve the quality of life for those affected.

Protein Name: DNA Polymerase Alpha 1, Catalytic Subunit

Functions: Catalytic subunit of the DNA polymerase alpha complex (also known as the alpha DNA polymerase-primase complex) which plays an essential role in the initiation of DNA synthesis. During the S phase of the cell cycle, the DNA polymerase alpha complex (composed of a catalytic subunit POLA1, a regulatory subunit POLA2 and two primase subunits PRIM1 and PRIM2) is recruited to DNA at the replicative forks via direct interactions with MCM10 and WDHD1. The primase subunit of the polymerase alpha complex initiates DNA synthesis by oligomerising short RNA primers on both leading and lagging strands. These primers are initially extended by the polymerase alpha catalytic subunit and subsequently transferred to polymerase delta and polymerase epsilon for processive synthesis on the lagging and leading strand, respectively. The reason this transfer occurs is because the polymerase alpha has limited processivity and lacks intrinsic 3' exonuclease activity for proofreading error, and therefore is not well suited for replicating long complexes. In the cytosol, responsible for a substantial proportion of the physiological concentration of cytosolic RNA:DNA hybrids, which are necessary to prevent spontaneous activation of type I interferon responses (PubMed:27019227)

The "POLA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POLA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets